Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

A legfontosabb adatok

Ki végzi
National Cancer Institute (NCI)
Hol
Ames, Ann Arbor, Appleton, Baker City, Basking Ridge, Belpre, Billings, Boise, Boone, Brighton, Brownstown, Burlington, Caldwell, Canton, Cape Girardeau, Centralia, Charlotte, Chelsea, Chillicothe, City of Saint Peters, Clackamas, Clarkston, Clinton, Clinton Township, Columbus, Commack, Coon Rapids, Coral Gables, Coral Springs, Creve Coeur, Danville, Dearborn, Decatur, Deerfield Beach, Delaware, Detroit, Doral, Dublin, Eau Claire, Edina, Edmonds, Effingham, Farmington Hills, Flint, Fort Dodge, Gahanna, Gastonia, Glens Falls, Goldsboro, Grove City, Harrison, Hollywood, Irvine, Issaquah, Jackson, Jacksonville, Jefferson, La Crosse, Lancaster, Lansing, Lima, Livonia, Mansfield, Marietta, Marion, Marshalltown, Marshfield, Mattoon, Maywood, Meridian, Miami, Middletown, Minneapolis, Minocqua, Monroe, Montvale, Mount Vernon, Nampa, New York, Newark, Newberg, North Miami, Novi, O'Fallon, Ontario, Oregon City, Perrysburg, Plantation, Pontiac, Portland, Portsmouth, Rice Lake, Richmond, Rochester, Saginaw, Saint Joseph, Saint Louis Park, Saint Paul, Seattle, Springfield, St Louis, Stevens Point, Tawas City, Toledo, Tucson, Uniondale, Urbana, Webster, West Bloomfield, Westerville, Weston, Wyandotte, Ypsilanti és Zanesville (Egyesült Államok)Mind a 150 helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
92 fő, tervezett
Kezdés
2022. jan. 5.
Várható befejezés
2028. márc. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Computed Tomography
  • Ibrutinib
  • Positron Emission Tomography
  • Rituximab
  • Venetoclax
  • Zanubrutinib
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 34 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants must have had a confirmed diagnosis of Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL). Participants must have measurable disease as determined by IgM protein quantification; IgM Spike: ≥ 500 mg/dL (≥ 5 g/L); Extramedullary disease: The manifestation of a lymphoid mass outside of the bone marrow, resulting in enlargement in extramedullary organs such as the lymph nodes or spleen. Note: all participants must have measurable IgM spike, but are not required to have extramedullary disease
  • Testing to establish baseline disease status must be performed within 28 days prior to registration
  • Participants must have at least one of the criteria to require therapy for WM including:; Anemia; Thrombocytopenia; Neuropathy related to WM; Symptomatic hyperviscosity or serum viscosity levels ≥ 4.0 centipoises; WM associated glomerulonephritis or renal disease, bulky disease, or constitutional symptoms; Constitutional symptoms can be described as:; Unintentional weight loss >= 10% within the previous 6 months prior to screening; Fevers higher than 100.5 degrees Fahrenheit (F) or 38.0 degrees Celsius (C) for 2 or more weeks prior to screening without evidence of infection; Night sweats for more than 1 month prior to screening without evidence of infection; Clinically relevant fatigue which is not relieved by rest due to WM
  • Participants who require ongoing use or received a moderate or strong CYP3A inducer, moderate or strong CYP3A inhibitor, P-gp inhibitor within 7 days prior to the first dose of study drug will be excluded from the study. If such participants can be safely switched to an alternative agent, then the participants will be eligible to enroll
  • Participants must not have had prior systemic therapy. Prior therapy with rituximab will be allowed as long as the last rituximab dose was at least 6 months prior to registration
  • Participants must be >= 18 years of age
  • Participants must have history and physical exam within 28 days prior to registration
  • Participants must have Zubrod performance status =< 2
  • Participants must have evidence of adequate renal function, as defined by creatinine clearance (CrCl) >= 30 mL/min. Values must be obtained within 14 days prior to registration
  • Total bilirubin =< 1.5 x IULN (institutional upper limit of the norm) (within 14 days prior to registration)
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x IULN (within 14 days prior to registration)
  • Alkaline phosphatase =< 3 x IULN (within 14 days prior to registration)
  • Platelet count >= 50,000 cells/mm\^3 (within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
  • Hemoglobin >= 7.0 g/dL (within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
  • Absolute neutrophil count (ANC) >= 1,000 cells/mm\^3 (within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
  • Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 6 months prior to registration
  • Participants must be able to take and swallow oral medication (capsules) whole. Participants may not have any known impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
  • Participants must not be intolerant to rituximab
  • Participants must not have known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding localized skin and nail bed fungal infections) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) 4 weeks prior to registration
  • Participants must not be seropositive for hepatitis C (except in the setting of sustained virologic response, defined as undetectable viral load at least 12 weeks after completion of antiviral therapy). Hepatitis C virus (HCV) testing is only required if clinically indicated or if the participant has a history of HCV
  • Participants must not consume grapefruit, Seville oranges or starfruit within 3 days prior to the first dose of venetoclax
  • Participants must not be pregnant or nursing because venetoclax has not been studied in pregnant or nursing women and the mechanism of action is expected to cause fetal harm. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condom, cervical ring, sponge, etc.). This also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures throughout the study and for at least 30 days after competition of therapy
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years or watchful waiting is appropriate in the opinion of the treating physician. Also, malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 5 years, is permissible consideration of eligibility for this trial
  • Participants must be offered the opportunity to participate in specimen banking
  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
  • As a part of the Oncology Participant Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
  • CROSSOVER CRITERIA: Participants must have been registered and received treatment in the IR/Z or VR arm and must show progression of disease at any time during cycles 3-24
  • CROSSOVER CRITERIA: In case of transformation to intermediate or high-grade lymphoma or development of Bing-Neel syndrome the participants will not undergo registration step 2 crossover and will be taken off the study
  • CROSSOVER CRITERIA: Participants must have Zubrod performance status =< 2
  • CROSSOVER CRITERIA: Participants must have evidence of adequate renal function, as defined by creatinine clearance (CrCl) >= 30 mL/min. Values must be obtained within 14 days prior to registration
  • CROSSOVER CRITERIA: Participants must have no evidence of marked hepatic dysfunction on any recent liver function tests within 14 days prior to registration
  • CROSSOVER CRITERIA: Platelet count >= 50,000 cells/mm\^3 (without within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
  • CROSSOVER CRITERIA: Hemoglobin >= 7.0 g/dL (without within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
  • CROSSOVER CRITERIA: Absolute neutrophil count (ANC) >= 1,000 cells/mm\^3 (without within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration

Helyszínek itt: Egyesült Államok

  • Mary Greeley Medical CenterAmes, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • McFarland Clinic - AmesAmes, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • Trinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • ThedaCare Regional Cancer CenterAppleton, Egyesült ÁllamokContact: Yazhini Vallatharasu (principal investigator)Résztvevőt keres
  • Saint Alphonsus Cancer Care Center-Baker CityBaker City, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Memorial Sloan Kettering Basking RidgeBasking Ridge, Egyesült ÁllamokContact: Maria L. Palomba (principal investigator)Résztvevőt keres
  • Strecker Cancer Center-BelpreBelpre, Egyesült ÁllamokNo longer taking part
  • Saint Vincent Frontier Cancer CenterBillings, Egyesült ÁllamokContact: Patrick W. Cobb (principal investigator)Résztvevőt keres
  • Saint Alphonsus Cancer Care Center-BoiseBoise, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • McFarland Clinic - BooneBoone, Egyesült ÁllamokNo longer taking part
  • Trinity Health IHA Medical Group Hematology Oncology - BrightonBrighton, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health Medical Center - BrightonBrighton, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Henry Ford Cancer Institute-DownriverBrownstown, Egyesült ÁllamokContact: Vijayalakshmi Donthireddy (principal investigator)Résztvevőt keres
  • Lahey ClinicBurlington, Egyesült ÁllamokContact: Julio Hajdenberg (principal investigator)Résztvevőt keres
  • Saint Alphonsus Cancer Care Center-CaldwellCaldwell, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology - CantonCanton, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health Medical Center - CantonCanton, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Saint Francis Medical CenterCape Girardeau, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Centralia Oncology ClinicCentralia, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Carolinas Medical Center/Levine Cancer InstituteCharlotte, Egyesült ÁllamokContact: Manisha Bhutani (principal investigator)Résztvevőt keres
  • Chelsea HospitalChelsea, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Adena Regional Medical CenterChillicothe, Egyesült ÁllamokNo longer taking part
  • Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, Egyesült ÁllamokNo longer taking part
  • Providence Cancer Institute Clackamas ClinicClackamas, Egyesült ÁllamokNo longer taking part
  • Hematology Oncology Consultants-ClarkstonClarkston, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Newland Medical Associates-ClarkstonClarkston, Egyesült ÁllamokNo longer taking part
  • Southeastern Medical Oncology Center-ClintonClinton, Egyesült ÁllamokContact: Samer S. Kasbari (principal investigator)Résztvevőt keres
  • Henry Ford Macomb Hospital-Clinton TownshipClinton Township, Egyesült ÁllamokContact: Vijayalakshmi Donthireddy (principal investigator)Résztvevőt keres
  • Columbus Oncology and Hematology Associates IncColumbus, Egyesült ÁllamokNo longer taking part
  • Doctors HospitalColumbus, Egyesült ÁllamokNo longer taking part
  • Grant Medical CenterColumbus, Egyesült ÁllamokNo longer taking part
  • Mount Carmel East HospitalColumbus, Egyesült ÁllamokNo longer taking part
  • Mount Carmel Health Center WestColumbus, Egyesült ÁllamokNo longer taking part
  • Riverside Methodist HospitalColumbus, Egyesült ÁllamokNo longer taking part
  • The Mark H Zangmeister CenterColumbus, Egyesült ÁllamokNo longer taking part
  • Memorial Sloan Kettering CommackCommack, Egyesült ÁllamokContact: Maria L. Palomba (principal investigator)Résztvevőt keres
  • Mercy HospitalCoon Rapids, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • UM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables, Egyesült ÁllamokContact: Georgios Pongas (principal investigator)Résztvevőt keres
  • UM Sylvester Comprehensive Cancer Center at Coral SpringsCoral Springs, Egyesült ÁllamokContact: Georgios Pongas (principal investigator)Résztvevőt keres
  • Siteman Cancer Center at West County HospitalCreve Coeur, Egyesült ÁllamokNo longer taking part
  • Carle at The RiverfrontDanville, Egyesült ÁllamokContact: Priyank P. Patel (principal investigator)Résztvevőt keres
  • Henry Ford Medical Center-FairlaneDearborn, Egyesült ÁllamokContact: Vijayalakshmi Donthireddy (principal investigator)Résztvevőt keres
  • Cancer Care Specialists of Illinois - DecaturDecatur, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • UM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach, Egyesült ÁllamokContact: Georgios Pongas (principal investigator)Résztvevőt keres
  • Delaware Health Center-Grady Cancer CenterDelaware, Egyesült ÁllamokNo longer taking part
  • Grady Memorial HospitalDelaware, Egyesült ÁllamokNo longer taking part
  • Henry Ford HospitalDetroit, Egyesült ÁllamokContact: Vijayalakshmi Donthireddy (principal investigator)Résztvevőt keres
  • Wayne State University/Karmanos Cancer InstituteDetroit, Egyesült ÁllamokContact: Andrew Kin (principal investigator)Résztvevőt keres
  • UM Sylvester Comprehensive Cancer Center at DoralDoral, Egyesült ÁllamokContact: Georgios Pongas (principal investigator)Résztvevőt keres
  • Dublin Methodist HospitalDublin, Egyesült ÁllamokNo longer taking part
  • Marshfield Medical Center-EC Cancer CenterEau Claire, Egyesült ÁllamokNo longer taking part
  • Minnesota Oncology - EdinaEdina, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Swedish Cancer Institute-EdmondsEdmonds, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Carle Physician Group-EffinghamEffingham, Egyesült ÁllamokContact: Priyank P. Patel (principal investigator)Résztvevőt keres
  • Crossroads Cancer CenterEffingham, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Weisberg Cancer Treatment CenterFarmington Hills, Egyesült ÁllamokContact: Andrew Kin (principal investigator)Résztvevőt keres
  • Cancer Hematology Centers - FlintFlint, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Genesys Hurley Cancer InstituteFlint, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Hurley Medical CenterFlint, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Genesee Hematology Oncology PCFlint, Egyesült ÁllamokNo longer taking part
  • McFarland Clinic - Trinity Cancer CenterFort Dodge, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • Central Ohio Breast and Endocrine SurgeryGahanna, Egyesült ÁllamokNo longer taking part
  • Levine Cancer Institute-GastonGastonia, Egyesült ÁllamokContact: Manisha Bhutani (principal investigator)Résztvevőt keres
  • Glens Falls HospitalGlens Falls, Egyesült ÁllamokNo longer taking part
  • Southeastern Medical Oncology Center-GoldsboroGoldsboro, Egyesült ÁllamokContact: Samer S. Kasbari (principal investigator)Résztvevőt keres
  • Mount Carmel Grove City HospitalGrove City, Egyesült ÁllamokNo longer taking part
  • Memorial Sloan Kettering WestchesterHarrison, Egyesült ÁllamokContact: Maria L. Palomba (principal investigator)Résztvevőt keres
  • UM Sylvester Comprehensive Cancer Center at HollywoodHollywood, Egyesült ÁllamokContact: Georgios Pongas (principal investigator)Résztvevőt keres
  • City of Hope at Irvine LennarIrvine, Egyesült ÁllamokContact: Benjamin M. Heyman (principal investigator)Résztvevőt keres
  • Swedish Cancer Institute-IssaquahIssaquah, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Allegiance HealthJackson, Egyesült ÁllamokContact: Vijayalakshmi Donthireddy (principal investigator)Résztvevőt keres
  • Mayo Clinic in FloridaJacksonville, Egyesült ÁllamokContact: Sikander Ailawadhi (principal investigator)Résztvevőt keres
  • Southeastern Medical Oncology Center-JacksonvilleJacksonville, Egyesült ÁllamokContact: Samer S. Kasbari (principal investigator)Résztvevőt keres
  • McFarland Clinic - JeffersonJefferson, Egyesült ÁllamokNo longer taking part
  • Gundersen Lutheran Medical CenterLa Crosse, Egyesült ÁllamokContact: David E. Marinier (principal investigator)Résztvevőt keres
  • Fairfield Medical CenterLancaster, Egyesült ÁllamokNo longer taking part
  • University of Michigan Health - Sparrow LansingLansing, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Saint Rita's Medical CenterLima, Egyesült ÁllamokNo longer taking part
  • Trinity Health Saint Mary Mercy Livonia HospitalLivonia, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • OhioHealth Mansfield HospitalMansfield, Egyesült ÁllamokNo longer taking part
  • Marietta Memorial HospitalMarietta, Egyesült ÁllamokNo longer taking part
  • OhioHealth Marion General HospitalMarion, Egyesült ÁllamokNo longer taking part
  • McFarland Clinic - MarshalltownMarshalltown, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • Marshfield Medical Center-MarshfieldMarshfield, Egyesült ÁllamokNo longer taking part
  • Carle Physician Group-Mattoon/CharlestonMattoon, Egyesült ÁllamokContact: Priyank P. Patel (principal investigator)Résztvevőt keres
  • Loyola University Medical CenterMaywood, Egyesült ÁllamokContact: Patrick A. Hagen (principal investigator)Résztvevőt keres
  • Idaho Urologic Institute-MeridianMeridian, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • UM Sylvester Comprehensive Cancer Center at KendallMiami, Egyesült ÁllamokContact: Georgios Pongas (principal investigator)Résztvevőt keres
  • University of Miami Miller School of Medicine-Sylvester Cancer CenterMiami, Egyesült ÁllamokContact: Georgios Pongas (principal investigator)Résztvevőt keres
  • Memorial Sloan Kettering MonmouthMiddletown, Egyesült ÁllamokContact: Maria L. Palomba (principal investigator)Résztvevőt keres
  • Abbott-Northwestern HospitalMinneapolis, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Hennepin County Medical CenterMinneapolis, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Marshfield Medical Center - MinocquaMinocqua, Egyesült ÁllamokNo longer taking part
  • Atrium Health Union/LCI-UnionMonroe, Egyesült ÁllamokContact: Manisha Bhutani (principal investigator)Résztvevőt keres
  • Memorial Sloan Kettering BergenMontvale, Egyesült ÁllamokContact: Maria L. Palomba (principal investigator)Résztvevőt keres
  • Knox Community HospitalMount Vernon, Egyesült ÁllamokNo longer taking part
  • Saint Alphonsus Cancer Care Center-NampaNampa, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Memorial Sloan-Kettering Cancer CenterNew York, Egyesült ÁllamokContact: Maria L. Palomba (principal investigator)Résztvevőt keres
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York, Egyesült ÁllamokNo longer taking part
  • Licking Memorial HospitalNewark, Egyesült ÁllamokContact: Aruna C. Gowda (principal investigator)Résztvevőt keres
  • Newark Radiation OncologyNewark, Egyesült ÁllamokNo longer taking part
  • Providence Newberg Medical CenterNewberg, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • University of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami, Egyesült ÁllamokContact: Georgios Pongas (principal investigator)Résztvevőt keres
  • Henry Ford Medical Center-ColumbusNovi, Egyesült ÁllamokContact: Vijayalakshmi Donthireddy (principal investigator)Résztvevőt keres
  • Cancer Care Center of O'FallonO'Fallon, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Saint Alphonsus Cancer Care Center-OntarioOntario, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Providence Willamette Falls Medical CenterOregon City, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Mercy Health - Perrysburg HospitalPerrysburg, Egyesült ÁllamokNo longer taking part
  • UM Sylvester Comprehensive Cancer Center at PlantationPlantation, Egyesült ÁllamokContact: Georgios Pongas (principal investigator)Résztvevőt keres
  • Michigan Healthcare Professionals PontiacPontiac, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group-Alice Gustafson CenterPontiac, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health Saint Joseph Mercy Oakland HospitalPontiac, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Providence Portland Medical CenterPortland, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Providence Saint Vincent Medical CenterPortland, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Southern Ohio Medical CenterPortsmouth, Egyesült ÁllamokNo longer taking part
  • Marshfield Medical Center-Rice LakeRice Lake, Egyesült ÁllamokNo longer taking part
  • VCU Massey Comprehensive Cancer CenterRichmond, Egyesült ÁllamokContact: Bharadhwaj Kolipakkam (principal investigator)Résztvevőt keres
  • Mayo Clinic in RochesterRochester, Egyesült ÁllamokContact: Sikander Ailawadhi (principal investigator)Résztvevőt keres
  • University of RochesterRochester, Egyesült ÁllamokContact: Clive S. Zent (principal investigator)Résztvevőt keres
  • MyMichigan Medical Center SaginawSaginaw, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Oncology Hematology Associates of Saginaw Valley PCSaginaw, Egyesült ÁllamokNo longer taking part
  • Heartland Regional Medical CenterSaint Joseph, Egyesült ÁllamokContact: Jay W. Carlson (principal investigator)Résztvevőt keres
  • Park Nicollet Clinic - Saint Louis ParkSaint Louis Park, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Regions HospitalSaint Paul, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • United HospitalSaint Paul, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Swedish Medical Center-First HillSeattle, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Southern Illinois University School of MedicineSpringfield, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Springfield ClinicSpringfield, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Springfield Memorial HospitalSpringfield, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Mercy Hospital SouthSt Louis, Egyesült ÁllamokContact: Jay W. Carlson (principal investigator)Résztvevőt keres
  • Siteman Cancer Center at Christian HospitalSt Louis, Egyesült ÁllamokNo longer taking part
  • Siteman Cancer Center-South CountySt Louis, Egyesült ÁllamokNo longer taking part
  • Washington University School of MedicineSt Louis, Egyesült ÁllamokNo longer taking part
  • Marshfield Medical Center-River Region at Stevens PointStevens Point, Egyesült ÁllamokContact: Adedayo A. Onitilo (principal investigator)Résztvevőt keres
  • MyMichigan Medical Center TawasTawas City, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Mercy Health - Saint Anne HospitalToledo, Egyesült ÁllamokNo longer taking part
  • Mercy Health - Saint Vincent HospitalToledo, Egyesült ÁllamokNo longer taking part
  • Banner University Medical Center - TucsonTucson, Egyesült ÁllamokContact: Muhammad Husnain (principal investigator)Résztvevőt keres
  • University of Arizona Cancer Center-North CampusTucson, Egyesült ÁllamokContact: Muhammad Husnain (principal investigator)Résztvevőt keres
  • Memorial Sloan Kettering NassauUniondale, Egyesült ÁllamokContact: Maria L. Palomba (principal investigator)Résztvevőt keres
  • Carle Cancer CenterUrbana, Egyesült ÁllamokContact: Priyank P. Patel (principal investigator)Résztvevőt keres
  • Wilmot Cancer Institute at WebsterWebster, Egyesült ÁllamokContact: Clive S. Zent (principal investigator)Résztvevőt keres
  • Henry Ford West Bloomfield HospitalWest Bloomfield, Egyesült ÁllamokContact: Vijayalakshmi Donthireddy (principal investigator)Résztvevőt keres
  • Saint Ann's HospitalWesterville, Egyesült ÁllamokNo longer taking part
  • Marshfield Medical Center - WestonWeston, Egyesült ÁllamokContact: Adedayo A. Onitilo (principal investigator)Résztvevőt keres
  • Henry Ford Wyandotte HospitalWyandotte, Egyesült ÁllamokContact: Vijayalakshmi Donthireddy (principal investigator)Résztvevőt keres
  • Huron Gastroenterology PCYpsilanti, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Genesis Healthcare System Cancer Care CenterZanesville, Egyesült ÁllamokNo longer taking part

A vizsgálatról

Mit akar kideríteni a vizsgálat

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib, a type of tyrosine kinase inhibitor, blocks a protein called BTK, which may help keep cancer cells from growing. Giving venetoclax and rituximab may work better in treating patients with previously untreated Waldenstrom's macroglobulinemia than ibrutinib with rituximab or zanubrutinib alone.

A vizsgálat 2 csoportja

  • Arm I (ibrutinib + rituximab or zanubrutinib)Már használt kezelés, összehasonlításként

    Patients receive ibrutinib PO QD on days 1-28 of cycles 1-24 and rituximab IV on days 1, 8, 15, and 22 of cycles 2 and 5, or zanubrutinib PO QD or BID on days 1-28 of cycles 1-24. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease during Arm I may receive rituximab and venetoclax as in Arm II for up to an additional 24 cycles. Patients undergo CT or PET/CT and bone marrow biopsy and aspiration as well as blood sample collection throughout the trial.

    Kezelés: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Positron Emission Tomography, Rituximab és Zanubrutinib

  • Arm II (venetoclax, rituximab)A vizsgált kezelés

    Patients receive venetoclax PO QD on days 1-28 of each cycle and rituximab IV on days 1, 8, 15, and 22 of cycles 2 and 5. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease during Arm II may receive ibrutinib and rituximab as in Arm I for up to an additional 24 cycles. Patients undergo CT or PET/CT and bone marrow biopsy and aspiration as well as blood sample collection throughout the trial.

    Kezelés: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab és Venetoclax

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase II Randomized Study Comparing BTK Inhibitors (Ibrutinib Plus Rituximab or Zanubrutinib Alone) vs. BCL-2 Inhibitor (Venetoclax) and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
A regiszteradat frissítve
2026. november 12.